As BIQO-19 possesses an enhanced ADMET profile and effective antiproliferative activity in EGFR-TKI-resistant NSCLC cells, further studies were performed in order to elucidate its molecular mechanism of action in EGFR-TKI-resistant H1975 cells. Here, EGFR is linked to non-small cell lung carcinoma.